TruCheck™

What is TruCheck™

Circulating Tumour Cells (CTCs) are cancer cells that shed from tumours into the bloodstream, playing a crucial role in cancer metastasis. Their detection offers a non-invasive method to monitor cancer progression, assess treatment efficacy, and predict metastasis.

TruCheck™, an advanced diagnostic test, utilises cutting-edge technology to analyse blood samples in order to identify CTCs, enabling the early detection of various cancers, in asymptomatic individuals. By detecting CTCs, TruCheck™ allows early diagnosis and treatment, which is valuable in improving the prognosis for those with solid organ cancers.

TruCheck™ - Advantages

  • Peace of Mind

    Cancer screening test for peace of mind

  • No Wait Times

    No wait times for appointments

  • Non-Invasive

    Non-invasive and can be done without visiting a hospital or a screening centre

  • 70 Solid Organ Cancers

    Cost-effective, provides screening for 70 solid organ cancers

  • Just A Blood Test

    No risks associated with invasive procedures

  • Avoid Unnecessary Procedures

    Helps avoid procedures that may be retrospectively found unnecessary

What types of cancer can TruCheck™ detect?

  • Melanoma

  • Prostate

  • Head and Neck

  • Salivary Gland

  • Lung

  • Gynaecological

  • Breast

  • Liver

  • Biliary Tract

  • Gastrointestinal

  • Soft Tissue

  • Mesothelioma

  • Central Nervous System

  • Urinary Tract

  • Adrenal

  • Osteosarcomas

Full list of cancers

This test can detect a variety of types solid organ cancers listed below which can affect various organs. Click on each one to reveal more information.

  • Bile Duct, Breast, Colon, Duodenum, Oesophagogastric Junction, Oesophagus, Gall Bladder, Ileum, Jejunum, Liver, Lung, Ovary, Pancreas, Prostate, Rectum, Stomach, Thyroid, Uterus, Salivary Duct, Kidney, Cervix.

  • Esophagus, Gall Bladder, Lung, Cervix.

  • Astrocytoma, Glioblastoma, Oligodendroglioma.

  • Colon, Duodenum, Ileum, Jejunum, Rectum, Stomach.

  • Cutaneous, Mucosal.

  • Pleural, Peritoneal

  • Adrenal, Colon, Duodenum, Oesophagus, Ileum, Jejunum, Lung, Pancreas, Prostate, Rectum, Thymus, Appendix. 

  • Anorectum, Buccal Mucosa, Cervix, Oesophagus, Hard Palate, Larynx, Lip, Lung, Oral Cavity, Paranasal Sinuses, Penis, Pharynx, Pyriform Fossa, Retromolar Trigone, Skin, Soft palate, Tongue, Tonsil, Vulva, Vagina.

  • Urinary Bladder, Renal Pelvis, Ureter.

What to expect

Comprehensive Screening

Multi-cancer early detection tests aim to screen for a variety of cancers simultaneously. These tests may analyse blood samples for specific markers associated with different types of cancer.

Potential Early Detection

The primary goal is to identify cancers at an early stage when they may be more treatable. Detecting cancers early can increase the chances of successful treatment and improve overall outcomes.

Minimally Invasive

Many multi-cancer tests are minimally invasive and involve a simple blood draw. This contrasts with traditional cancer screening methods that may be more invasive, such as colonoscopies or mammograms.

Convenience

Compared to undergoing separate screenings for various types of cancer, a multi-cancer early detection test offers the convenience of a single test for multiple cancers.

What not to expect

Perfect Accuracy

While these tests have shown promise, they are not perfect. False positives and false negatives can occur. Follow-up diagnostic tests are often necessary to confirm results and rule out false positives.

Complete Replacement for Traditional Screenings

Multi-cancer tests are not intended to replace traditional cancer screenings, such as mammograms, colonoscopies, or Pap smears. Rather, they may complement existing screening methods.

Diagnosis Without Confirmation

Positive results from a multi-cancer test do not provide a definitive diagnosis. Further diagnostic procedures, such as imaging studies or biopsies, are typically required to confirm the presence of cancer.

Elimination of Other Risk Factors

Multi-cancer tests do not eliminate the importance of managing other risk factors for cancer, such as lifestyle factors (e.g., smoking, diet, physical activity) and regular screenings for specific types of cancer with established screening protocols.

Universal Applicability

Not all multi-cancer tests are suitable for everyone. Their utility may vary based on factors such as age, family history, and individual health risks.

Possible Test Outcomes

  • A Positive Result of Circulating Tumor Cells (CTCs) Detected

    CTCs indicative of TruCheck™ positivity have been detected in the given blood sample which is suggestive of higher risk of presence of cancer. The test will be able to indicate the likely organ of origin and malignancy type.  Individuals with positive findings will be counselled by our team.  We would advise further diagnostic tests be carried out to investigate these findings further. The results will be interpreted in the context of the individual’s clinical risk factors. 

  • A Negative Result with Circulating Tumor Cells (CTCs) Not Detected

    Circulating Tumor Cells (CTCs), indicative of TruCheck™ positivity were not detected in the given sample. This therefore suggests that there is a lower risk of the presence of cancer. However, no test is perfect and a negative TruCheck™ report does not completely exclude the possibility of cancer as some cancers may not shed detectable tumor cells in the blood.

Understanding Sensitivity and Specificity of Tests

Sensitivity (True Positive Rate)

Sensitivity is the ability of a test to correctly identify individuals who have the disease. A high sensitivity means that the test is good at correctly identifying true positive cases.

Specificity (True Negative Rate)

Specificity is the ability of a test to correctly identify individuals who do not have the disease. A high specificity means that the test is good at correctly identifying true negative cases.

Test Performance of TruCheck™

Sensitivity (True Positive Rate)

This is the ability of the test to correctly identify patients with cancer. TruCheck™ has shown an overall sensitivity of 88.24% (ranges from 65-89%) for detection and localisation of solid organ malignancies, meaning that for every 100 patients tested who have cancer, it will correctly identify 88 of those patients, resulting in a 12% false negative rate (i.e. 12 out of 100 will be told they do not have cancer but actually do have it) 

Specificity (True Negative Rate)

The ability of the test to correctly identify people without cancer. TruCheck™ has an overall specificity of 96.3% (ranges from 96-99%) - meaning that for every 100 people tested, that do not have cancer, TruCheck™ will correctly identify 96 of these individuals, resulting in a 4% false positive rate (i.e. 4 out of 100 will be told they do have the cancer but actually do not have it). 

FAQ

  • No. Your healthcare provider can advise if TruCheck™ is suitable for you to use alongside standard of care screening.

  • Yes. A healthcare provider must approve and prescribe a TruCheck™ test for you

  • No. In these circumstances, you should seek urgent medical advice. TruCheck™ is for healthy, asymptomatic individuals.

  • These are carried out in the clinic either as part of the Cancer Health Check, or ass an addition to other health checks. If it is an addition the price of this is £950. If you would like it carried out at home then please contact us. The restrictions to home visits apply. It will not be carried out by our out of hours service. 

  • You take the test on a yearly basis as an annual cancer check test.

  • TruCheck™ can help people without any symptoms, who have a higher cancer risk, due to family history or age. Please see the section above to learn more.  If you need further advice please contact us to discuss this. 

  • The test may in some cases, produce false positive / false negative results due to biological and analytical variations. 

    Only solid cancers are checked with TruCheck™. TruCheck™ cannot detect blood or lymphatic system cancers because CTCs are associated with solid organ malignancies.